Literature DB >> 8083133

Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro.

R Wollman1, J Yahalom, R Maxy, J Pinto, Z Fuks.   

Abstract

PURPOSE: To study the effect of epidermal growth factor (EGF) on the radiation sensitivity of MCF-7 breast cancer cells. METHODS AND MATERIALS: Radiation dose survival curves were generated for MCF-7 cells under conditions of hormonal deprivation. Epidermal growth factor and/or a monoclonal antibody to its receptor (mAb-225) were added prior to irradiation. Cell cycle distribution was determined by flow cytometry and cellular glutathione (GSH) levels were measured by a glutathione reductase assay.
RESULTS: Under hormonal deprivation (control), more than 90% of the MCF-7 cells were arrested in G0/G1 phase and the D(o) of their survival curve was 0.66 +/- .01 Gy. The addition of EGF resulted in (a) growth stimulation; (b) increased percentage of cells in the S-phase of the cell cycle; (c) increased radioresistance (D(o) = 0.81 +/- .04 Gy; p < .05, compared with controls); (d) increased cellular GSH level. The EGF effect on radiation response was observed in a time- and dose-dependent manner. The addition of mAb-225 blocked the ability of EGF to enhance growth and radioresistance (D(o) = 0.68 +/- .03 Gy).
CONCLUSION: Epidermal growth factor stimulates the growth and when administered prior to irradiation increases the radioresistance of hormone-deprived MCF-7 cells. These effects are inhibited by a specific antibody to the EGF receptor. Epidermal growth factor concomitantly increased the fraction of S-phase cells and intracellular GSH levels. This system of growth factor-altered radiosensitivity in human breast cancer cells provides a useful model for the study of the radiation response mechanisms in human malignancy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8083133     DOI: 10.1016/0360-3016(94)90523-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  23 in total

Review 1.  Concurrent chemoradiotherapy for inoperable stage III non-small-cell lung cancer.

Authors:  Robert MacRae; Hak Choy
Journal:  Curr Oncol Rep       Date:  2003-07       Impact factor: 5.075

Review 2.  HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer.

Authors:  Kazi M Ahmed; Ning Cao; Jian Jian Li
Journal:  Anticancer Res       Date:  2006 Nov-Dec       Impact factor: 2.480

3.  Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer.

Authors:  Tim J Kruser; Eric A Armstrong; Amol J Ghia; Shyhmin Huang; Deric L Wheeler; Robert Radinsky; Daniel J Freeman; Paul M Harari
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-10-01       Impact factor: 7.038

4.  Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines.

Authors:  Takashi Yamatodani; Lars Ekblad; Elisabeth Kjellén; Anders Johnsson; Hiroyuki Mineta; Johan Wennerberg
Journal:  J Cancer Res Clin Oncol       Date:  2008-09-24       Impact factor: 4.553

5.  EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients.

Authors:  Siwen Hu-Lieskovan; Daniel Vallbohmer; Wu Zhang; Dongyun Yang; Alexander Pohl; Melissa J Labonte; Peter P Grimminger; Arnulf H Hölscher; Robert Semrau; Dirk Arnold; Kathrin Dellas; Annelies Debucquoy; Karin Haustermans; Jean-Pascal H Machiels; Christine Sempoux; Claus Rödel; Matej Bracko; Vaneja Velenik; Heinz-Josef Lenz
Journal:  Clin Cancer Res       Date:  2011-06-14       Impact factor: 12.531

6.  Her-2 prognostic value in very early-stage breast cancer: a single-institution retrospective analysis.

Authors:  Pietro Sanpaolo; Viviana Barbieri; Piernicola Pedicini; Vincenzo Fusco
Journal:  Med Oncol       Date:  2011-02-26       Impact factor: 3.064

Review 7.  Linking the history of radiation biology to the hallmarks of cancer.

Authors:  Mary-Keara Boss; Robert Bristow; Mark W Dewhirst
Journal:  Radiat Res       Date:  2014-05-08       Impact factor: 2.841

8.  Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells.

Authors:  D M O'Rourke; G D Kao; N Singh; B W Park; R J Muschel; C J Wu; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

Review 9.  Cellular responses to EGFR inhibitors and their relevance to cancer therapy.

Authors:  Pinaki R Dutta; Amit Maity
Journal:  Cancer Lett       Date:  2007-03-23       Impact factor: 8.679

Review 10.  Molecular targeted treatment and radiation therapy for rectal cancer.

Authors:  Friederike Marquardt; Franz Rödel; Gianni Capalbo; Christian Weiss; Claus Rödel
Journal:  Strahlenther Onkol       Date:  2009-06-09       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.